Physician profile
Gilbert K Ong
NPI 1740310283
$1,432.72
in general payments reported to CMS, 2019-2025
15 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $57.40 · 2021: $60.78 · 2022: $140 · 2023: $449 · 2024: $295 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $454.05 | 2019-2024 | |
| Abbvie INC. | $344.75 | 2020-2025 | |
| Janssen Biotech, INC. | $126.57 | 2019 | |
| Gilead Sciences, INC. | $116.36 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.82 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $66.70 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $49.68 | 2019-2025 | Entyvio |
| Lilly USA, LLC | $46.54 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $38.77 | 2021-2022 | |
| Allergan, INC. | $37.38 | 2019 | |
| Merck Sharp & Dohme LLC | $19.12 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.69 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $16.29 | 2021 | |
| Celgene Corporation | $16.17 | 2021 | |
| Novo Nordisk INC | $13.83 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.